➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
Express Scripts
Mallinckrodt
McKinsey

Last Updated: October 17, 2021

DrugPatentWatch Database Preview

Amoxapine - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic drug sources for amoxapine and what is the scope of freedom to operate?

Amoxapine is the generic ingredient in two branded drugs marketed by Upsher Smith Labs, Watson Labs, Watson Pharms Teva, and Lederle, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for amoxapine. One supplier is listed for this compound.

Summary for amoxapine
Recent Clinical Trials for amoxapine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4
Research Foundation for Mental Hygiene, Inc.Phase 2

See all amoxapine clinical trials

Pharmacology for amoxapine

US Patents and Regulatory Information for amoxapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upsher Smith Labs AMOXAPINE amoxapine TABLET;ORAL 072878-001 Jun 28, 1991 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Upsher Smith Labs AMOXAPINE amoxapine TABLET;ORAL 072944-001 Jun 28, 1991 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Watson Labs AMOXAPINE amoxapine TABLET;ORAL 072691-004 Aug 28, 1992 RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Watson Labs AMOXAPINE amoxapine TABLET;ORAL 072691-003 Aug 28, 1992 RX No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for amoxapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
Express Scripts
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.